Case File
efta-efta00973011DOJ Data Set 9OtherFrom: "Fenn, Patrick"
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00973011
Pages
1
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: "Fenn, Patrick"
To: 'Jeffrey Epstein' <[email protected]>
Subject: Your question and a question for you
Date: Fri, 11 Oct 2013 20:53:32 +0000
Hi Jeffrey. Has to do with potential implications under the anti-churning rules of section 197(f)(9) and the attribution
rules that are part of the regime. Basically denies a basis step up in property contributed to a partnership if a number of
requirements are met, including that the contributing party has or acquires a more than 20% interest in the transferee
partnership following the exchange. For this purpose, an individual partner is deemed to own what his or her partners
own, and family members are deemed to own what a family member owns. If Leon or his children were to acquire
(directly or indirectly) then the anti-churning rules could disallow the step up on an exchange for TRA purposes. I'll look
at attribution rules to see if there is a way to cut off the problem.
While I have you, the Company has been discussing again refinancing the existing AMH debt (and only refinancing the
debt). Any reason not to do that?
From: Jeffrey Epstein [[email protected]]
Sent: Friday, October 11, 2013 3:18 PM
To: Fenn, Patrick
Subject:
john suydam tells me there are tax reasons why leon or his children cannot buy class a shares in the market
place. he says there are adverse tax consequences. ? facts?
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
IRS Circular 230 Notice Requirement: This communication is not given in the form of a covered
opinion, within the meaning of Circular 230 issued by the United States Secretary of the Treasury.
Thus, we are required to inform you that you cannot rely upon any tax advice contained in this
communication for the purpose of avoiding United States federal tax penalties. In addition, any tax
advice contained in this communication may not be used to promote, market or recommend a transaction
to another party.
The information contained in this e-mail message is intended only for the personal and confidential
use of the recipient(s) named above. If you have received this communication in error, please notify
us immediately by e-mail, and delete the original message.
EFTA00973011
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Wire Ref
refinancingRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.